A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
The purpose of this study is to find out whether tinengotinib in combination with abiraterone acetate and prednisone or enzalutamide is a safe treatment that causes few or mild side effects in people with metastatic castration-resistant prostate cancer (mCRPC).
Prostate Cancer
DRUG: Tinengotinib|DRUG: abiraterone acetate with prednisone|DRUG: Enzalutamide
RP2D, Evaluate DLT occurrence to confirm safety and RP2D, From the start of study treatment through the DLT window (28 days)|Objective Response Rate (ORR), by local investigator's assessment per PCWG3-modified RECIST v1.1 in participants with baseline measurable disease OR rate of PSA decline of â‰¥ 50% from baseline in patients with a baseline PSA of 2.0 ng/mL or above, up to 6months
Time to Radiographic Response (phase II), Time to radiographic response by local investigator's assessment per PCWG3-modified RECIST v1.1 in participants with baseline measurable disease (CR) or Partial Response (PR) per Prostate Cancer Clinical Trials Working Group 3 (PCWG3)-modified RECIST v1.1 in patients with baseline measurable disease, From start of study treatment until 6 months post study treatment start
The purpose of this study is to find out whether tinengotinib in combination with abiraterone acetate and prednisone or enzalutamide is a safe treatment that causes few or mild side effects in people with metastatic castration-resistant prostate cancer (mCRPC).